APA (7th ed.) Citation

Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., . . . Wenham, R. M. (2013). The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. The lancet oncology, 14(9), 882-892. https://doi.org/10.1016/S1470-2045(13)70240-7

Chicago Style (17th ed.) Citation

Sandhu, Shahneen K., et al. "The Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK4827) in BRCA Mutation Carriers and Patients with Sporadic Cancer: A Phase 1 Dose-escalation Trial." The Lancet Oncology 14, no. 9 (2013): 882-892. https://doi.org/10.1016/S1470-2045(13)70240-7.

MLA (9th ed.) Citation

Sandhu, Shahneen K., et al. "The Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK4827) in BRCA Mutation Carriers and Patients with Sporadic Cancer: A Phase 1 Dose-escalation Trial." The Lancet Oncology, vol. 14, no. 9, 2013, pp. 882-892, https://doi.org/10.1016/S1470-2045(13)70240-7.